Company intelligence / Profile preview

Inotec AMD

Cambridge / Waterbeach, England, United Kingdomnatroxwoundcare.com ↗

Ownership: Private
Development stage: Other

Overview

The company’s flagship product, NATROX O₂, delivers continuous humidified oxygen directly to the wound bed and has been clinically proven to accelerate healing of chronic and acute wounds. Clinical studies report up to a 90% healing rate within 8–12 weeks for both acute and chronic wounds. The device has regulatory approvals including FDA clearance and CE mark. Recent Series C funding ($33M/£26M) supports US expansion after securing national reimbursement for the device. The technology has been recognized as a top UK medtech innovation.

Therapeutic areas: DermatologyEndocrinology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Amadeus Capital Partners (investor/backer from inception)broad distribution/reimbursement partnerships globally.

Beyond the preview

Go deeper on Inotec AMD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inotec AMD.

Explore the full profile